Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1523854
This article is part of the Research Topic Integrating Molecular Mechanisms, Immunotherapy, and Drug Sensitivity in Cancer Immunology and Oncology View all 13 articles

Comprehensive Single-Cell Pan-Cancer Atlas Unveils IFI30+ Macrophages as Key Modulators of Intra-tumoral Immune Dynamics

Provisionally accepted
Lihe Jiang Lihe Jiang 1Peili Wang Peili Wang 1Yixuan Hou Yixuan Hou 1Jingying Chen Jingying Chen 2Hua Li Hua Li 2*
  • 1 School of Basic Medicine, Youjiang Medical University for Nationalities, Baise, Guangx, China
  • 2 Department of General Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China

The final, formatted version of the article will be published soon.

    The convergence of macrophage-targeted strategies with immune checkpoint blockade therapies defines a pivotal avenue in contemporary tumor therapy. Identifying robust genetic regulators in this context is imperative.Methods: This study elucidates IFI30 role in enhancing Major Histocompatibility Complex II (MHC-II) restriction antigen processing. Despite its recognition in cancer immunotherapy, IFI30 remains a nascent focus. Our approach involves a multi-omics analysis of IFI30 tumor immunological profile in the macrophage-mediated Tumor Microenvironment (TME), spanning various cancers and bolstered by rigorous co-culture laboratory work.Results: IFI30 predominantly localizes in monocyte/macrophage populations, correlating strongly with immune cell infiltration. Substantiated by single-cell analysis, IFI30 exhibits significant functional enrichment in immune-related pathways. Co-expression with immunerelated genes, including MHC elements and immune checkpoints, further validates its relevance.Our study positions IFI30 as a promising immunotherapeutic target. Pan-cancer analyses and glioblastoma multiforme (GBM) investigations collectively underscore IFI30 potential as a TME modulator, particularly in its interaction with M2-macrophages. IFI30 emerges as a prospective intervention point in the immunotherapeutic landscape.

    Keywords: IFI30, ScRNA-seq, Spatial transcriptomics, Pan-cancer, macrophage, Immunotherapy

    Received: 06 Nov 2024; Accepted: 07 Jan 2025.

    Copyright: © 2025 Jiang, Wang, Hou, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hua Li, Department of General Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.